公开(公告)号：US09862758B2

公开(公告)日：2018-01-09

申请号：US15070572

申请日：2016-03-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yan Chen ,  Elena Getmanova ,  Martin C. Wright ,  Alan S. Harris ,  Ai Ching Lim ,  Jochem Gokemeijer ,  Lin Sun ,  Michael Wittekind

IPC: C07K14/78 ,  C07H21/04 ,  C12N15/09 ,  C07K19/00 ,  C07K14/47 ,  C07K14/52 ,  C07K16/28 ,  C07K16/30 ,  A61K38/39 ,  A61K38/00 ,  A61K39/00

CPC classification number: C07K14/78 ,  A61K38/00 ,  A61K38/39 ,  A61K2039/505 ,  C07H21/04 ,  C07K14/4703 ,  C07K14/52 ,  C07K16/2863 ,  C07K16/30 ,  C07K19/00 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2318/20 ,  C12N15/09

Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.

公开(公告)号：US11708405B2

公开(公告)日：2023-07-25

申请号：US16728757

申请日：2019-12-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Mohan Srinivasan ,  Shrikant Deshpande ,  Qihong Zhao ,  Huadong Sun ,  Ginger Rakestraw ,  Guodong Chen ,  Richard Y. Huang ,  Steven Sheriff ,  Cristian Rodriguez ,  John P. Throup ,  Rose A. Dibella

IPC: A61K39/395 ,  C07K16/24 ,  A61K47/68 ,  A61K9/00 ,  C07K16/00 ,  A61K39/00

CPC classification number: C07K16/24 ,  A61K9/0019 ,  A61K47/6845 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.